Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study.
Masatoshi Kudo, Ghassan K Abou-Alfa, Zhenggang Ren et al.
✦ AI-curated · Sources linked
In 30 seconds
The EMERALD-3 study evaluated the efficacy and safety of combining STRIDE (tremelimumab and durvalumab) with or without lenvatinib and transarterial chemoembolisation (TACE) in patients with embolisation-eligible hepatocellular carcinoma (HCC). This phase 3, randomised trial included 760 participants. The combination of STRIDE plus lenvatinib plus TACE resulted in a median progression-free survival of 13.0 months compared to 9.8 months for TACE alone (HR 0.70; p=0.0007).
Key findings
- Median progression-free survival was 13.0 months for STRIDE plus lenvatinib plus TACE versus 9.8 months for TACE alone (HR 0.70; p=0.0007).
- The study included 760 participants, with 83% being male and 72% Asian.
- Overall survival median follow-up was 24.6 months for STRIDE plus lenvatinib plus TACE.
- The trial was conducted across 177 medical sites in 21 countries.
Why it matters
This study provides evidence that combining immunotherapy with lenvatinib and TACE may improve progression-free survival in patients with embolisation-eligible HCC, potentially influencing treatment strategies in this population.